Congratulations to Emily Cox who defended her PhD thesis on August 12, 2019! Her thesis focused on understanding and engineering monoclonal antibodies that preferentially recognize glycan structures. Specifically, Emily developed a "humanized" antibody against the cancer-associated oligosaccharide polysialic acid (polySia) and showed that it could be leveraged for possible therapeutic intervention by reformatting as a synthetic immunotherapy known as an antibody-drug conjugate (ADC). During her time at Cornell, Emily collaborated closely with the Alabi and Paszek labs on the topic of antibody-based targeting of the glycocalyx. Emily is now pursuing a position in the biopharmaceutical industry.